» Articles » PMID: 26915916

Approach to the Highly Sensitized Kidney Transplant Candidate

Overview
Specialty Nephrology
Date 2016 Feb 27
PMID 26915916
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

For patients with ESRD, kidney transplant offers significant survival and quality-of-life advantages compared with dialysis. But for patients seeking transplant who are highly sensitized, wait times have traditionally been long and options limited. The approach to the highly sensitized candidate for kidney transplant has changed substantially over time owing to new advances in desensitization, options for paired donor exchange (PDE), and changes to the deceased-donor allocation system. Initial evaluation should focus on determining living-donor availability because a compatible living donor is always the best option. However, for most highly sensitized candidates this scenario is unlikely. For candidates with an incompatible donor, PDE can improve the prospects of finding a compatible living donor but for many highly sensitized patients the probability of finding a match in the relatively small pools of donors in PDE programs is limited. Desensitization of a living donor/recipient pair with low levels of incompatibility is another reasonable approach. But for pairs with high levels of pathologic HLA antibodies, outcomes after desensitization for the patient and allograft are less optimal. Determining the degree of sensitization by calculated panel-reactive antibody (cPRA) is critical in counseling the highly sensitized patient on expected wait times to deceased-donor transplant. For candidates with a high likelihood of finding a compatible deceased donor in a reasonable time frame, waiting for a kidney is a good strategy. For the candidate without a living donor and with a low probability of finding a deceased-donor match, desensitization on the waiting list can be considered. The approach to the highly sensitized kidney transplant candidate must be individualized and requires careful discussion among the transplant center, patient, and referring nephrologist.

Citing Articles

Evaluating the efficacy of basiliximab versus no induction in low-immunological-risk kidney transplant recipients: a propensity score matched analysis.

Zhang D, Wen J, Dong J, Ma R, Li S, Wu J Ren Fail. 2025; 47(1):2460729.

PMID: 39978365 PMC: 11843659. DOI: 10.1080/0886022X.2025.2460729.


Evolving adeno-associated viruses for gene transfer to the kidney via cross-species cycling of capsid libraries.

Rosales A, Blondel L, Hull J, Gao Q, Aykun N, Peek J Nat Biomed Eng. 2025; .

PMID: 39910375 DOI: 10.1038/s41551-024-01341-0.


Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus.

Furian L, Heemann U, Bengtsson M, Bestard O, Binet I, Bohmig G Transpl Int. 2025; 37:13886.

PMID: 39867871 PMC: 11758882. DOI: 10.3389/ti.2024.13886.


Improving the Prioritization of Heart Transplantation Candidates for Optimal Clinical Outcomes: A Narrative Review.

Thuan P, Khang C, Dinh N Curr Cardiol Rep. 2025; 27(1):8.

PMID: 39777580 DOI: 10.1007/s11886-024-02150-2.


Development of a checklist framework for kidney transplantation.

Nicolau-Raducu R, Ciancio G, Raveh Y Front Transplant. 2024; 3:1412391.

PMID: 38993790 PMC: 11235342. DOI: 10.3389/frtra.2024.1412391.


References
1.
Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran P . Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation. 1996; 61(11):1586-92. DOI: 10.1097/00007890-199606150-00007. View

2.
Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen J, Vernerey D, Aubert O . IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol. 2015; 27(1):293-304. PMC: 4696574. DOI: 10.1681/ASN.2014111120. View

3.
Montgomery R . Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant. 2010; 10(3):449-57. DOI: 10.1111/j.1600-6143.2009.03001.x. View

4.
Vo A, Peng A, Toyoda M, Kahwaji J, Cao K, Lai C . Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010; 89(9):1095-102. DOI: 10.1097/TP.0b013e3181d21e7f. View

5.
Lefaucheur C, Loupy A, Hill G, Andrade J, Nochy D, Antoine C . Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010; 21(8):1398-406. PMC: 2938596. DOI: 10.1681/ASN.2009101065. View